BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS
A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethyl-ene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.
1 - 19 . (canceled)
20 . A biodegradable drug delivery composition comprising:
(a) a biodegradable triblock copolymer having the formula:
A v -B w -A x
wherein A is a polyester and B is polyethylene glycol, wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and
(b) a biodegradable diblock copolymer having the formula:
C y -A z
wherein A is a polyester and C is an end-capped polyethylene glycol wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable CA diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition; and (c) at least one pharmaceutically hydrophobic active principle.
21 . The biodegradable drug delivery composition according to claim 20 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine base or medroxyprogesterone acetate.
22 . A biodegradable drug delivery composition comprising:
(a) a biodegradable triblock copolymer having the formula:
A v -B w -A x
wherein A is a polyester and B is polyethylene glycol , wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x, v and x being ester repeat units and w being ethylene oxide repeat units and v=x or v≠x; and
(b) a biodegradable diblock copolymer having the formula:
C y -A z
wherein A is a polyester and C is an end-capped polyethylene glycol wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, y being the number of ethylene oxide repeat units and z the number of ester repeat units, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable CA diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition; and (c) at least one pharmaceutically hydrophobic active principle.
23 . The biodegradable drug composition according to claim 22 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine base or medroxyprogesterone acetate.
24 . A biodegradable drug delivery composition comprising:
(a) a biodegradable triblock copolymer having the formula:
PLA v -PEG w -PLA x
wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and
(b) a biodegradable diblock copolymer having the formula:
PEG y -PLA z
wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition and wherein the PEG in the diblock is end-capped; and (c) at least one pharmaceutically hydrophobic active principle
25 . The biodegradable drug delivery composition according to claim 24 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate.
26 . A biodegradable drug delivery composition is provided, which comprises:
(a) a biodegradable triblock copolymer having the formula:
PLA v -PEG w -PLA x
wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and
(b) a biodegradable diblock having the formula:
PEG y -PLA z
wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition and wherein the PEG in the diblock is end capped and (c) at least one pharmaceutically hydrophobic active principle.
27 . The biodegradable drug delivery composition according to claim 28 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate.
28 . A biodegradable drug delivery composition, which comprises:
(a) a biodegradable triblock copolymer present in an amount of 3.0% to 45% (w %/w %) or 2% to 45% (w %/w %)of the total composition having the formula:
PLA v -PEG w -PLA x
wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273; and
(b) a biodegradable diblock copolymer present in an amount of 8.0% to 50% (w %/w %) of the total composition having the formula:
PEG y -PLA z
wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition and wherein the PEG in the diblock is end capped and (c) at least one pharmaceutically hydrophobic active principle is present in an amount of 1% to 20% (w %/w %) or 1% to 40% (w %/w %) of the total composition.
29 . The biodegradable drug delivery composition according to claim 28 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate.
30 . The biodegradable drug delivery compositions according to claim 20 , wherein a lactic acid to ethylene oxide molar ratio in said composition is between 0.5 to 3.5 or between 0.5 to 2.5 or between 0.5 to 22.3 for the triblock copolymer and between 2 to 6 or between 0.8 to 13 or between 3 to 5 for the diblock copolymer.
31 . The biodegradable drug delivery compositions according to claim 20 , wherein said compositions are an injectable liquid that when inserted into the body of an animal or plant becomes a hardened implant.
32 . A method for preparing the biodegradable drug delivery composition of the invention, said method comprising:
(i) dissolving in an organic solvent (a) a biodegradable ABA type block copolymer having the formula:
A v -B w -A x
wherein A is a polyester and B is polyethylene glycol wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 wherein v=x or v≠x; and (b) a biodegradable diblock copolymer having the formula:
C y -A z
wherein A is a polyester and C is an end-capped polyethylene glycol wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, in a ratio of 1:3 to 1:8 or 1:1 to 1:19 or 3.2 to 1:19 to form a polymer mixture; and
(ii) adding at least one pharmaceutically hydrophobic active principle to said polymer mixture.
33 . The method for preparing the biodegradable drug delivery compositions according to claim 32 , the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate to said polymer mixture.
34 . A method for preparing the biodegradable drug delivery composition of the present invention said method comprising: (i) dissolving in an organic solvent (a) a biodegradable ABA type block copolymer having the formula:
A v -B w -A x
wherein A is a polyester and B is polyethylene glycol wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 wherein v=x or v≠x; and (b) a biodegradable diblock copolymer having the formula:
C y -A z
wherein A is a polyester and C is an end-capped polyethylene glycol wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, in a ratio of 1:3 to 1:8 or 1:1 to 1:19 or 3.2 to 1:19 to form a polymer mixture; (ii) adding at least one pharmaceutically hydrophobic active principle to said polymer mixture; and (iii) evaporating said solvent.
35 . The method according to claim 34 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate.
36 . A method for preparing the biodegradable drug delivery composition of the present invention said method comprising: (i) dissolving in an organic solvent (a) a biodegradable ABA type block copolymer having the formula:
A v -B w -A x
wherein A is a polyester and B is polyethylene glycol wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 , v and x being ester repeat units and w being ethylene oxide repeat units wherein v=x or v≠x; and (b) a biodegradable diblock copolymer having the formula:
C y -A z
wherein A is a polyester and C is an end-capped polyethylene glycol wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, y being the number of ethylene oxide repeat units and z the number of ester repeat units, in a ratio of 1:3 to 1:8 or 1:1 to 1:19 or 3.2 to 1:19 to form a polymer mixture; (ii) adding at least one pharmaceutically hydrophobic active principle to said polymer mixture; and (iii) evaporating said solvent.
37 . The method according to claim 36 , wherein the at least one pharmaceutically hydrophobic active principle one of which is risperidone, ivermectin, levonorgestrel, cyclosporine, progesterone, bupivacaine or medroxyprogesterone acetate.
38 . The method according to claim 32 , the organic solvent is be present in an amount of 40% to 74% (w %/w %) or 30% to 70% (w %/w %) or 26% to 90% (w %/w %) of the total composition.
39 . The biodegradable drug delivery compositions according to claim 21 , wherein said compositions are an injectable liquid that when inserted into the body of an animal or plant becomes a hardened implant.